Physician profile
Stephen Wall
NPI 1033503388
$6,115.37
in general payments reported to CMS, 2019-2025
28 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $613 · 2021: $1,189 · 2022: $589 · 2023: $1,041 · 2024: $852 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Education: $16.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.58 |
| Education | $16.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,063.36 | 2019-2025 | Synergy, Ilab Ultrasound Imaging System, General - Brady |
| Biotronik INC. | $606.36 | 2019-2023 | Amvia Edge |
| Astrazeneca Pharmaceuticals Lp | $448.82 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $447.93 | 2019-2025 | Lifevest |
| Amgen INC. | $438.02 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $364.22 | 2021-2025 | Aveir, Assurity |
| Janssen Pharmaceuticals, INC | $235.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.21 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $155.80 | 2019-2025 | |
| Pfizer INC. | $136.01 | 2019-2025 | |
| Medtronic, INC. | $128.96 | 2022-2024 | Attain Command + Surevalve, Micra |
| E.R. Squibb & Sons, L.L.C. | $106.81 | 2019-2025 | Eliquis |
| Alnylam Pharmaceuticals INC. | $97.97 | 2023-2025 | Amvuttra, Onpattro |
| Inari Medical, INC. | $96.52 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Celgene Corporation | $86.05 | 2023-2024 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.24 | 2024-2025 | Wegovy |
| Chiesi USA, INC. | $71.95 | 2019-2025 | Cleviprex |
| Merck Sharp & Dohme LLC | $66.41 | 2023-2025 | Verquvo |
| Heartflow, INC. | $62.27 | 2021 | |
| Sanofi-Aventis U.S. LLC | $56.26 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $51.37 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $37.24 | 2019 | |
| Shockwave Medical, INC | $31.82 | 2021 | |
| Exact Sciences Corporation | $27.72 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $22.36 | 2024 | Voquezna |
| Bridgebio Pharma, INC. | $14.73 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $13.78 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.75 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.